News | May 22, 2024
AstraZeneca sets ambition to deliver US$ 80 billion revenue by 2030
Launch of 20 new medicines expected by 2030
Launch of 20 new medicines expected by 2030
Sanofi will leverage this partnership to provide access to proprietary data to develop AI models
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
_256_384.jpeg)
ASG Group of Eye Hospitals has 165+ branches in 85+ cities across India and abroad
Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
Additional data from APPRAISE ATP trial reinforce modular therapy approach
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
The collaboration aims to bolster healthcare entrepreneurship
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
The award recognizes powerful science–industry collaborations for social good
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
